ArticleFrontiers in cardiovascular medicine2025
Development and validation of a nomogram to predict the risk of type II endoleak after endovascular aneurysm repair.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Type II endoleak (T2EL) is the most common complication following endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA). T2EL may lead to aneurysm sac expansion and rupture. Identifying high-risk patients is crucial for prophylaxis and early intervention. Methods: This single-center retrospective study included 332 patients who underwent EVAR for infrarenal AAA. Demographic, clinical, anatomical, and medication-related data were collected. A nomogram was developed based on significant predictors. Its performance was assessed by receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: T2EL occurred in 70 (21.08%) of 332 patients. Multivariate logistic regression revealed six independent predictors: age, smoking status, intraluminal thrombus (ILT), number of patent lumbar arteries (LA), inferior mesenteric artery (IMA) diameter, and IMA patency. The nomogram demonstrated excellent calibration and strong predictive ability, with an area under the curve (AUC) of 0.806 (training set) and 0.758 (validation set). DCA showed clinical benefit across threshold probabilities of 1%-66% and 79%-92% in the training set, and 1%-84% in the validation set. Conclusion: The proposed nomogram effectively integrates clinical and anatomical factors to assess the risk of T2EL after EVAR. It may help identify patients requiring intensified surveillance or early interventions to mitigate complications. Further multicenter, prospective studies are needed to validate the nomogram's applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.